About: Pramlintide

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pramlintide Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B628E-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Jones MC: Therapies for diabetes: pramlintide and exenatide. Am Fam Physician. 2007 Jun 15;75(12):1831-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17619527 # Ryan GJ, Jobe LJ, Martin R: Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther. 2005 Oct;27(10):1500-12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16330288 # Edelman S, Maier H, Wilhelm K: Pramlintide in the treatment of diabetes mellitus. BioDrugs. 2008;22(6):375-86. doi: 10.2165/0063030-200822060-00004. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18998755 # Kleppinger EL, Vivian EM: Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother. 2003 Jul-Aug;37(7-8):1082-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12841822 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	Approximately 48 minutes (en)
http://linked.open...ugbank/indication	For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy. (en)
sameAs	Pramlintide
Title	Pramlintide (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB01278/identifier/drugbank/DB01278 http://linked.opendata.cz/resource/drugbank/drug/DB01278/identifier/kegg-drug/D05595 http://linked.opendata.cz/resource/drugbank/drug/DB01278/identifier/national-drug-code-directory/66780-115-02 http://linked.opendata.cz/resource/drugbank/drug/DB01278/identifier/pharmgkb/PA164781394 http://linked.opendata.cz/resource/drugbank/drug/DB01278/identifier/wikipedia/Pramlintide
http://linked.open...mechanismOfAction	Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin. Amylin has activity in a number of gastrointestinal and glucodynamic systems, and by mimicking its activity, pramlintide acts to improve glycemic control through modulation of the rate of gastric emptying, prevention of post-prandial rise in glucagon levels, and by increasing sensations of satiety, thereby reducing caloric intake and potentiating weight loss. There appears to be at least three distinct receptor complexes that bind with high affinity to amylin. All three complexes contain the calcitonin receptor at the core, plus one of three Receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3. (en)
http://linked.open...drugbank/packager	Baxter International Inc. Ivax pharmaceuticals inc sub teva pharmaceuticals usa Hollister-Stier Laboratories LLC Mylan pharmaceuticals inc Neuman Distributors Inc. Norwich Pharmaceuticals Inc. Abbott laboratories pharmaceutical products div
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/5686411 http://linked.opendata.cz/resource/drugbank/patent/6610824
http://linked.open...outeOfElimination	Pramlintide is metabolized primarily by the kidneys. (en)
http://linked.open...nk/proteinBinding	Pramlintide does not extensively bind to blood cells or albumin (approximately 40% of the drug is unbound in plasma). (en)
http://linked.open...ogy/drugbank/salt	(en)
http://linked.open...ynthesisReference	Andreas Brunner, Oleg Werbitzky, Stephane Varray, Francesca Quattrini, Holger Hermann, Andrew Strong, Fernando Albericio, Judit Tulla-Puche, Yesica Garcia Ramos, "PROCESS FOR THE PRODUCTION OF PRAMLINTIDE." U.S. Patent US20100249370, issued September 30, 2010. (en)
foaf:page	http://www.drugs.com/cdi/pramlintide.html http://www.rxlist.com/cgi/generic/symlin.htm
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B6290-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B628F-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Pramlintide
http://linked.open...ugbank/absorption	The absolute bioavailability of a single subcutaneous dose of pramlintide is approximately 30 to 40%. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	151126-32-8 (en)
http://linked.open...gbank/containedIn	Symlin 0.6 mg/ml vial Symlinpen 60 pen injector SymlinPen 120 1000 mcg/ml Solution Two 2.7ml Syringes Per Box Symlin 600 mcg/ml Solution 5ml Vial

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 39 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software